Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02013674 · ClinicalTrials.gov registry record · Phase 2
The TRansendocardial Stem Cell Injection Delivery Effects on Neomyogenesis STudy (The TRIDENT Study)
A Phase 2 study, sponsored by Joshua M Hare.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT02013674 is a Phase 2 study that has completed, run by Joshua M Hare. The registered enrollment target is 30 participants.
The verdict
NCT02013674, a Phase 2 study, has completed, sponsored by Joshua M Hare.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
Thirty (30) patients with chronic ischemic left ventricular dysfunction secondary to MI scheduled to undergo cardiac catheterization will be enrolled in the study. This is a phase II study intended to gain additional safety and efficacy assessments among two dose levels previously studied in a phase I setting.
Interventions
- BIOLOGICAL Allogeneic hMSCs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-02-13 |
| Est. Completion | 2017-09-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02013674
The ClinicalTrials.gov registry entry for NCT02013674 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Joshua M Hare, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Allogeneic hMSCs is the first listed.
NCT02013674 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02013674 about?
NCT02013674 is a clinical study titled "The TRansendocardial Stem Cell Injection Delivery Effects on Neomyogenesis STudy (The TRIDENT Study)". Thirty (30) patients with chronic ischemic left ventricular dysfunction secondary to MI scheduled to undergo cardiac catheterization will be enrolled in the study. This is a phase II study intended to gain additional safety and efficacy assessments among two dose levels previously studied in a phase...
What is the current status of trial NCT02013674?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2014-02-13. Estimated completion is 2017-09-18.
What interventions are being tested in trial NCT02013674?
The interventions under investigation include: Allogeneic hMSCs (BIOLOGICAL).
Who is sponsoring clinical trial NCT02013674?
This trial is sponsored by Joshua M Hare, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.